Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combination in pre-clinical ovarian cancer (OC) models. We performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sudani, Hussein, Ni, Ying, Jones, Philip, Karakilic, Huseyin, Cui, Lei, Johnson, Lisa D. S., Rose, Peter G., Olawaiye, Alexander, Edwards, Robert P., Uger, Robert A., Lin, Gloria H. Y., Mahdi, Haider
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356752/
https://www.ncbi.nlm.nih.gov/pubmed/37468567
http://dx.doi.org/10.1038/s41698-023-00418-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356752/
https://www.ncbi.nlm.nih.gov/pubmed/37468567
http://dx.doi.org/10.1038/s41698-023-00418-4

Ejemplares similares